Catalog No.
DHM02301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a-nd
Clonality
Monoclonal
Target
HLA class II histocompatibility antigen, DRB1 beta chain, Human leukocyte antigen DRB1, HLA-DRB1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01911
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Iodine 131-ILym-1, Lym-1, Oncolym
Clone ID
Oncolym
Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma., PMID:32916604
The small molecule antibody mimic SH7139 targets a family of HLA-DRs expressed by B-cell lymphomas and other solid cancers., PMID:32588667
Neuromyelitis Optica (NMO IgG+) and Genetic Susceptibility, Potential Ethnic Influences., PMID:26923907
Reinfection of cytomegalovirus in renal transplantation., PMID:21701077
A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin's lymphoma also binds to canine B-cell lymphomas., PMID:20576295
Association between antibody response against cytomegalovirus strain-specific glycoprotein H epitopes and HLA-DR., PMID:19563400
Hexa-arginine enhanced uptake and residualization of selective high affinity ligands by Raji lymphoma cells., PMID:19383174
Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia., PMID:19148487
Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging., PMID:20443696
Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia., PMID:17875798
Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules., PMID:17803448
Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma., PMID:17786303
Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors., PMID:17651040
Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma., PMID:17631545
Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia., PMID:17373772
Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells., PMID:17257080
Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics., PMID:10541366
Lichenoid erythrodermic bullous pemphigoid of the African patient., PMID:9810884
Influence of the QKRAA/QRRAA/RRRAA motifs of the third hypervariable region of HLA-DRB1 in the development of rheumatoid arthritis., PMID:9002048
Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10., PMID:8917632
Shared epitopes of the HLA-DR10 molecule recognized by murine and human mAbs., PMID:7684257
For research use only. Not for human or drug use.
